Search Results
Mar 23, 2026, 06:00 ET Tensor Debuts World's First Personal Level 4 Robocar in the UK at the European AV Summit
Summit brought together regulators, insurers, researchers, OEMs, suppliers and city planners - the partners essential to responsibly introduce personal L4 ownership worldwide, with the UK positioned as a pioneering market that provides a roadmap for global deployment.In collaboration with strategic
More news about: Tensor Auto
Mar 22, 2026, 23:14 ET Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody
More news about: Harbour BioMed
Mar 22, 2026, 22:20 ET Henlius informa sus resultados de 2025: Crecimiento sostenido tanto en ingresos como en beneficios
Henlius continúa impulsando su cartera de productos innovadores, con activos clave como dulpatatug (HLX22, un nuevo epítopo anti-HER2 mAb) y HLX43 (PD-L1 ADC) que se encuentran en fases clínicas críticas.Gracias a sus capacidades integradas que abarcan I+D, operaciones clínicas, regulación, fabricación
More news about: Henlius
Mar 22, 2026, 22:18 ET Henlius présente ses résultats pour 2025 : croissance soutenue du chiffre d'affaires et du bénéfice, progression de la validation de l'innovation et des opérations mondiales
Henlius continue de faire progresser son pipeline d'innovations, avec des actifs clés tels que dulpatatug (HLX22, nouvel épitope anti-HER2 mAb) et HLX43 (PD-L1 ADC) qui entrent dans des phases cliniques critiques.Grâce à ses capacités intégrées en matière de R&D, d'opérations cliniques, de réglementation,
More news about: Henlius
Mar 22, 2026, 22:14 ET Henlius gibt Ergebnisse für 2025 bekannt: Anhaltendes Wachstum bei Umsatz und Gewinn, Ausbau der Innovationsvalidierung und der weltweiten Geschäftstätigkeit
gleichzeitig seine Innovationspipeline weiter voran und wichtige Wirkstoffe wie Dulpatatug (HLX22, ein neuartiger Epitop-Anti-HER2-mAb) und HLX43 (PD-L1-ADC) treten nun in entscheidende klinische Phasen ein.Gestützt auf seine integrierten Kompetenzen in den Bereichen Forschung und Entwicklung, klinische
More news about: Henlius
Mar 22, 2026, 21:27 ET RyzoBee kündigt geplanten Start der Root Series auf Kickstarter für das 2. Quartal 2026 an und bringt modulare RootMaker-Elektronik für Maker und 3D-Drucker-Kreative nach Nordamerika und Europa
rter-fur-das-2-quartal-2026-an-und-bringt-modulare-rootmaker-elektronik-fur-maker-und-3d-drucker-kreative-nach-nordamerika-und-europa-302721597.html
More news about: RyzoBee
Mar 22, 2026, 20:00 ET Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
24 weeks. The treatment period of the trial was one year. The primary endpoint was the proportion of patients with serum uric acid (sUA) < 360 μmol/L at week 24.The Principal Investigator of the Study, Professor Zou Hejian from Huashan Hospital, Fudan University,
More news about: Innovent Biologics
Mar 21, 2026, 15:50 ET EL LEXUS ES 2026 SALE AL MERCADO CON MODELOS TOTALMENTE ELÉCTRICOS; EL NUEVO HÍBRIDO LLEGARÁ PRONTO
ruedas.Cada ES 2026 comparte una carrocería y un estilo inspirados en el elegante concepto Lexus LF-ZC. Las luces LED de circulación diurna en forma de L se sitúan sobre los faros LED dobles y flanquean una superficie entallada que evoca el diseño de la parrilla trapezoidal de Lexus, y una prominente línea
More news about: Lexus
Mar 21, 2026, 07:54 ET WYBOT Unveils S3, Redefining Hands-Free Pool Cleaning
returns to its dock when the battery is low or after completing a cleaning cycle, recharges itself, and transfers collected debris into a shore-based 10L self-sanitising debris bin. This reduces manual maintenance to approximately once per month.Real-Time Control and Smart ConnectivityWith
More news about: WYBOTICS INC
Mar 21, 2026, 01:53 ET WYBOT Launches S3, Setting a New Standard in Pool Cleaning
returns to its dock when the battery is low or after completing a cleaning cycle, recharges itself, and transfers collected debris into a shore-based 10L self-sanitizing debris bin. This significantly reduces manual maintenance, requiring attention approximately once per month.Real-Time Control
More news about: WYBOTICS INC
Mar 20, 2026, 15:22 ET 11 Greenberg Traurig Attorneys Recognized in Colorado Super Lawyers 2026 Edition
Amy L. Kramer
More news about: Greenberg Traurig, LLP
Mar 20, 2026, 12:49 ET Lightedge Secures AWS Managed Service Provider Designation for the 9th Year, Reinforcing Cloud Excellence
addition to its AWS MSP designation, Lightedge is an AWS Premier Tier Services Partner and holds multiple AWS competencies including:L1 MSSP Security CompetencyHealthcare Consulting CompetencyDevOps Consulting CompetencyMigration and Modernization Consulting
More news about: Lightedge
Mar 20, 2026, 12:05 ET Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
4872.Cohen S., et al. J Prev Alzheimers Dis.2022;9(3):507-522.Morris JC. Neurology. 1993;43(11):2412-4.Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021; 12:3451.
More news about: Eisai Inc.
Mar 20, 2026, 12:00 ET NRMP Releases Results of the 2026 Main Residency Match for More Than 38,000 Future Residents
celebrating the hard work and achievements of thousands of students and graduates from across the country and the world," said NRMP President and CEO Donna L. Lamb, DHSc, MBA, BSN. "Match Day represents an extraordinary moment for future physicians, and we are proud to see the Main Residency Match welcoming
More news about: National Resident Matching Program
Mar 20, 2026, 11:13 ET JCP&L Encourages Customers to Explore Energy Bill Assistance Options
available assistance and payment programs.JCP&L serves 1.2 million New Jersey customers in the counties of Burlington, Essex, Hunterdon, Mercer, Middlesex, Monmouth, Morris, Ocean, Passaic, Somerset, Sussex, Union and Warren. Follow JCP&L on X
More news about: FirstEnergy Corp.
Mar 20, 2026, 10:57 ET VARON México Apoya el Bienestar Respiratorio con la Venta de Temporada de Primavera
requieren oxígeno continuo. Sus características incluyen:Flujo ajustable 1-6 L/min, concentración de oxígeno 28%-90%Nebulizador integrado que se activa a 6 L/minOperación silenciosa (≤45 dB) y batería reemplazableBolsa de transporte universal
More news about: Varon oxygen concentrator
Mar 20, 2026, 09:23 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
Meanwhile, Henlius continues to advance its innovation pipeline, with key assets including dulpatatug (HLX22, novel epitope anti-HER2 mAb) and HLX43 (PD-L1 ADC) entering critical clinical stages.Supported by its integrated capabilities spanning R&D, clinical operations, regulatory, manufacturing,
More news about: Henlius
Mar 20, 2026, 09:03 ET 復宏漢霖2025年業績：收入利潤持續雙增長，體系出海加速落地，創新管線進入密集驗證期
低疾病進展和死亡風險80%。除胃癌外，dulpatatug亦加速向乳腺癌等更多適應症拓展。其治療HER2低表達乳腺癌的II期研究已完成患者入組；同時，聯合HER2 ADC HLX87一線治療HER2陽性乳腺癌的II/III期研究已完成首例患者給藥。作為潛在同類最優（BIC）的廣譜抗腫瘤PD-L1 ADC，HLX43「單藥即管線」的潛力加速兌現。HLX43首次人體研究結果、多項實體瘤概念驗證數據先後亮相多場國際學術大會，展現出「高效、低毒
More news about: 復宏漢霖
Mar 20, 2026, 09:03 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in
More news about: Henlius
Mar 20, 2026, 09:00 ET Bernstein Litowitz Berger & Grossmann LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Driven Brands Holdings Inc. Common Stock
DRIVEN BRANDS HOLDINGS INC., JONATHAN G. FITZPATRICK, and TIFFANY L. MASON, Defendants.
More news about: Bernstein Litowitz Berger & Grossmann LLP
Mar 20, 2026, 08:54 ET Weinberger Divorce & Family Law Group Attorneys Recognized Among New Jersey's Top Family Law Professionals for 2026
HonoreesBari Z. Weinberger, Esq.Dianna C. Cavaliere, Esq.Robyn Howlett, Esq.Gina-Marie Izzo, Esq.Carmela L. Novi, Esq.Rachel E. Partyka, Esq.Richard A. Outhwaite, Esq.David F. Salvaggio, Esq.Salvatore A. Simeone, Esq.Aleida
More news about: Weinberger Divorce & Family Law Group, LLC.
Mar 20, 2026, 08:13 ET IFQM'S FIRST MSME SYMPOSIUM CALLS FOR A 'NATIONAL QUALITY SPRINT' TO INTEGRATE WITH GLOBAL VALUE CHAINS
250+ MSME CEOs, industry captains, and academia convene in Chennai Leaders from TVS, Boeing, Motherson, Maruti Suzuki, Cummins, L&T, Bosch, ZF, and Deloitte engage MSMEs on quality, global value chain integration, and digital transformationIFQM launches Quality Excellence
More news about: Indian Foundation for Quality Management (IFQM)
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
ATG-125 (B7-H3 × PD-L1 bispecific ADC): ATG-125 is an "IO + ADC" dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of IO therapies. By simultaneously blocking B7-H3- and PD-L1-mediated immunosuppressive
More news about: Antengene Corporation Limited
Mar 20, 2026, 05:00 ET Auger Chosen as the Premier Supply Chain Autonomy Platform on Microsoft Fabric
meetings and email chains, compensating for latency with inventory buffers and expedited shipments. This is the Coordination Tax. It doesn't appear on a P&L, but it compounds across every function it touches, trapping billions in working capital, excess inventory, and waste.Prior generations of supply
More news about: Auger
Mar 20, 2026, 05:00 ET XPENG Reports Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results
inflection point for Physical AI applications. Our goal is not only to grow our global market share of AI-defined vehicles and bridge the gap from L2+ assisted driving to L4 autonomous driving, but also to bring our second-generation VLA model to international markets and achieve scale production of advanced humanoid
More news about: XPeng Inc.